SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-021832
Filing Date
2022-08-10
Accepted
2022-08-10 08:30:52
Documents
51
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1326676
2 ex31-1.htm EX-31.1 18052
3 ex31-2.htm EX-31.2 18911
4 ex32-1.htm EX-32.1 6843
5 ex32-2.htm EX-32.2 6905
  Complete submission text file 0001493152-22-021832.txt   5796270

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE lixt-20220630.xsd EX-101.SCH 40933
7 XBRL CALCULATION FILE lixt-20220630_cal.xml EX-101.CAL 31135
8 XBRL DEFINITION FILE lixt-20220630_def.xml EX-101.DEF 206504
9 XBRL LABEL FILE lixt-20220630_lab.xml EX-101.LAB 331748
10 XBRL PRESENTATION FILE lixt-20220630_pre.xml EX-101.PRE 255299
45 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 988902
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39717 | Film No.: 221150527
SIC: 2834 Pharmaceutical Preparations